Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Rab coupling protein mediated endosomal recycling of N-cadherin influences cell motility.

Lindsay AJ, McCaffrey MW.

Oncotarget. 2016 Jul 9;8(62):104717-104732. doi: 10.18632/oncotarget.10513. eCollection 2017 Dec 1.

2.

A pilot study on the prevalence of DNA palindromes in breast cancer genomes.

Subramanian S, Chaparala S, Avali V, Ganapathiraju MK.

BMC Med Genomics. 2016 Dec 5;9(Suppl 3):73. doi: 10.1186/s12920-016-0232-3.

3.

An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors.

Luo J, Liu S, Leung S, Gru AA, Tao Y, Hoog J, Ho J, Davies SR, Allred DC, Salavaggione AL, Snider J, Mardis ER, Nielsen TO, Ellis MJ.

J Mol Diagn. 2017 Jan;19(1):147-161. doi: 10.1016/j.jmoldx.2016.09.007.

4.

Evolution of the NET (NocA, Nlz, Elbow, TLP-1) protein family in metazoans: insights from expression data and phylogenetic analysis.

Pereira F, Duarte-Pereira S, Silva RM, da Costa LT, Pereira-Castro I.

Sci Rep. 2016 Dec 8;6:38383. doi: 10.1038/srep38383.

5.

ZNF703 Overexpression may act as an oncogene in non-small cell lung cancer.

Baykara O, Dalay N, Kaynak K, Buyru N.

Cancer Med. 2016 Oct;5(10):2873-2878. doi: 10.1002/cam4.847. Epub 2016 Sep 20.

6.

A novel ER-microtubule-binding protein, ERLIN2, stabilizes Cyclin B1 and regulates cell cycle progression.

Zhang X, Cai J, Zheng Z, Polin L, Lin Z, Dandekar A, Li L, Sun F, Finley RL Jr, Fang D, Yang ZQ, Zhang K.

Cell Discov. 2015 Sep 8;1:15024. doi: 10.1038/celldisc.2015.24. eCollection 2015.

7.

Induction of proto-oncogene BRF2 in breast cancer cells by the dietary soybean isoflavone daidzein.

Koo J, Cabarcas-Petroski S, Petrie JL, Diette N, White RJ, Schramm L.

BMC Cancer. 2015 Nov 16;15:905. doi: 10.1186/s12885-015-1914-5.

8.

Targeting RTK Signaling Pathways in Cancer.

Regad T.

Cancers (Basel). 2015 Sep 3;7(3):1758-84. doi: 10.3390/cancers7030860. Review.

9.

Engineering targeted chromosomal amplifications in human breast epithelial cells.

Springer S, Yi KH, Park J, Rajpurohit A, Price AJ, Lauring J.

Breast Cancer Res Treat. 2015 Jul;152(2):313-21. doi: 10.1007/s10549-015-3468-2. Epub 2015 Jun 23.

10.

Elevated ZNF703 Protein Expression Is an Independent Unfavorable Prognostic Factor for Survival of the Patients with Head and Neck Squamous Cell Carcinoma.

Yang H, Jiang WQ, Cao Y, Sun YA, Wei J, An X, Zhang YC, Song M, Wang SS, Yuan ZY, Peng RJ, Chen TH, Li LR, Shi YX.

Dis Markers. 2015;2015:640263. doi: 10.1155/2015/640263. Epub 2015 Apr 29.

11.

Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.

André F, Cortés J.

Breast Cancer Res Treat. 2015 Feb;150(1):1-8. doi: 10.1007/s10549-015-3301-y. Epub 2015 Feb 13. Review.

12.

A global assessment of cancer genomic alterations in epigenetic mechanisms.

Shah MA, Denton EL, Arrowsmith CH, Lupien M, Schapira M.

Epigenetics Chromatin. 2014 Dec 4;7(1):29. doi: 10.1186/1756-8935-7-29. eCollection 2014.

13.

The FGF/FGFR axis as a therapeutic target in breast cancer.

Brady N, Chuntova P, Bade LK, Schwertfeger KL.

Expert Rev Endocrinol Metab. 2013 Jul;8(4):391-402. doi: 10.1586/17446651.2013.811910.

14.

Absent, small or homeotic 2-like protein (ASH2L) enhances the transcription of the estrogen receptor α gene through GATA-binding protein 3 (GATA3).

Qi J, Huo L, Zhu YT, Zhu YJ.

J Biol Chem. 2014 Nov 7;289(45):31373-81. doi: 10.1074/jbc.M114.579839. Epub 2014 Sep 25.

15.

KAT6A, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancer.

Turner-Ivey B, Guest ST, Irish JC, Kappler CS, Garrett-Mayer E, Wilson RC, Ethier SP.

Neoplasia. 2014 Aug;16(8):644-55. doi: 10.1016/j.neo.2014.07.007.

16.

NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism.

French CA, Rahman S, Walsh EM, Kühnle S, Grayson AR, Lemieux ME, Grunfeld N, Rubin BP, Antonescu CR, Zhang S, Venkatramani R, Dal Cin P, Howley PM.

Cancer Discov. 2014 Aug;4(8):928-41. doi: 10.1158/2159-8290.CD-14-0014. Epub 2014 May 29.

17.

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.

Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P, Tabernero J.

Ann Oncol. 2014 Mar;25(3):552-63. doi: 10.1093/annonc/mdt419. Epub 2013 Nov 20. Review.

18.

High expression of ZNF703 independent of amplification indicates worse prognosis in patients with luminal B breast cancer.

Reynisdottir I, Arason A, Einarsdottir BO, Gunnarsson H, Staaf J, Vallon-Christersson J, Jonsson G, Ringnér M, Agnarsson BA, Olafsdottir K, Fagerholm R, Einarsdottir T, Johannesdottir G, Johannsson OT, Nevanlinna H, Borg A, Barkardottir RB.

Cancer Med. 2013 Aug;2(4):437-46. doi: 10.1002/cam4.88. Epub 2013 May 22.

19.

Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers.

Tiong KH, Mah LY, Leong CO.

Apoptosis. 2013 Dec;18(12):1447-68. doi: 10.1007/s10495-013-0886-7. Review.

20.

Posttranscriptional regulation by RNA-binding proteins during epithelial-to-mesenchymal transition.

Aparicio LA, Abella V, Valladares M, Figueroa A.

Cell Mol Life Sci. 2013 Dec;70(23):4463-77. doi: 10.1007/s00018-013-1379-0. Epub 2013 May 29. Review.

Supplemental Content

Support Center